Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Complex and Mixed

ClinicalTrials.gov lists 538 trials for Neoplasms, Complex and Mixed or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 64.

MeSH D018193 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 131 Phase 1/2 Phase 1/2 35 Phase 2 Phase 2 168 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 44 Phase 4 Phase 4 5 Not applicable Not applicable 50 Observational Observational 97 Phase 1 Phase 1 131 Phase 1/2 Phase 1/2 35 Phase 2 Phase 2 168 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 44 Phase 4 Phase 4 5 Not applicable Not applicable 50 Observational Observational 97

Trials per phase (log scale)

1 more section with rows

Get the Neoplasms, Complex and Mixed report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Complex and Mixed trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 30

1990: 1 trials (Phase 2 1) 1992: 3 trials (Observational 2, Phase 2 1) 1993: 1 trials (Phase 3 1) 1994: 1 trials (Phase 1 1) 1995: 3 trials (Phase 3 2, Phase 2 1) 1996: 4 trials (Phase 3 2, Phase 2 2) 1997: 6 trials (Not applicable 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 1998: 11 trials (Phase 3 2, Phase 2 6, Phase 1 3) 1999: 6 trials (Phase 3 4, Phase 1/2 1, Phase 1 1) 2000: 10 trials (Phase 3 1, Phase 2 5, Phase 1/2 3, Phase 1 1) 2001: 13 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 5, Phase 1 4) 2002: 8 trials (Phase 3 1, Phase 2 4, Phase 1 3) 2003: 11 trials (Not applicable 2, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2004: 11 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 3, Phase 1 2) 2005: 15 trials (Observational 2, Not applicable 4, Phase 2 2, Phase 1 7) 2006: 23 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 9, Phase 1 6) 2007: 17 trials (Observational 2, Phase 3 4, Phase 2 5, Phase 1/2 1, Phase 1 5) 2008: 17 trials (Observational 7, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 2) 2009: 14 trials (Observational 5, Phase 3 3, Phase 2 3, Phase 1 3) 2010: 20 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 11) 2011: 24 trials (Observational 6, Not applicable 5, Phase 3 2, Phase 2 8, Phase 1/2 1, Phase 1 2) 2012: 16 trials (Observational 9, Phase 2 3, Phase 1 4) 2013: 8 trials (Observational 1, Not applicable 2, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2014: 11 trials (Observational 1, Not applicable 1, Phase 2 7, Phase 1 2) 2015: 14 trials (Observational 3, Phase 2 5, Phase 1 6) 2016: 17 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2017: 30 trials (Observational 4, Phase 3 2, Phase 2 13, Phase 1/2 3, Phase 1 8) 2018: 30 trials (Observational 2, Not applicable 4, Phase 3 1, Phase 2/3 1, Phase 2 14, Phase 1/2 2, Phase 1 6) 2019: 18 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 2 8, Phase 1 7) 2020: 29 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 11, Phase 1/2 2, Phase 1 6) 2021: 27 trials (Observational 5, Not applicable 3, Phase 3 1, Phase 2 7, Phase 1/2 3, Phase 1 8) 2022: 27 trials (Observational 8, Not applicable 4, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1/2 5, Phase 1 4) 2023: 20 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 4, Phase 1/2 2, Phase 1 5) 2024: 23 trials (Observational 5, Not applicable 3, Phase 3 1, Phase 2 9, Phase 1/2 2, Phase 1 3) 2025: 18 trials (Observational 4, Not applicable 3, Phase 2 3, Phase 1/2 1, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 22
2025 18
2024 23
2023 20
2022 27
2021 27
2020 29
2019 18
2018 30
2017 30

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 26 trials starting in 2026 and about 21 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 68 trials still running at the 2026-10-09 snapshot; registered median of 49 months across 327 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Complex and Mixed trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 131
Phase 1/2 35
Phase 2 168
Phase 2/3 4
Phase 3 44
Phase 4 5
Not applicable 50
Observational 97
Expanded access 4

How many Neoplasms, Complex and Mixed trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 15
Recruiting 80
Enrolling by invitation 1
Active, not recruiting 51
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Complex and Mixed trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 64
Children's Oncology Group 45
Pediatric Brain Tumor Consortium 9
European Organisation for Research and Treatment of Cancer - EORTC 8

Which drugs are being tested for Neoplasms, Complex and Mixed? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 38
(nab)-paclitaxel 18
NIVOLUMAB 15
PEMBROLIZUMAB 13
Irinotecan 12

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
or carboplatin 37
Etoposid 28
Vincristina 27
Doxorubicine 25
Cisplatin 1 21

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Complex and Mixed trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Disease progression 230 13
Neutrophil count decreased 146 11
Anemia 126 17
Death NOS 118 15
Febrile neutropenia 91 16

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Complex and Mixed? (4)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience. Pediatric blood & cancer 2007 Yes
Metaplastic breast cancer: prognosis and response to systemic therapy. Annals of oncology : official journal of the European Society for Medical Oncology 1999 Yes
Hemangioendothelioma. Seminars in diagnostic pathology 2013 No
Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Human pathology 2011 No

Sub-conditions in MeSH (18)

MeSH descendants one level down with at least one trial, most trials first.

+8 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages